Darren R. Shafren - Concepedia

Author

Darren R. Shafren

Also Known As

D R Shafren, D. R. Shafren, D. Shafren, D.R. SHAFREN, D.R. Shafren, Darren R Shafren, Darren R. SHAFREN, Darren R. Shafren, Darren Shafren

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

University of Newcastle Australia Huntsman Cancer Institute Providence Portland Medical Center University of Utah Oncology Specialists

About

Darren R. Shafren is an author at University of Newcastle Australia specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	32	1.5K
2	Cell Biology	11	12	990
3	Natural Sciences	1	1	11
4	Cellular Physiology	1	1	27
5	Gastroenterology	1	1	24

Darren R. Shafren

Publications

2.7K

Citations

H-Index

Page 1

	Year	Citations
Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment Darren R. Shafren, Richard C. Bates, Michael Agrez, Journal of Virology Cell Surface MoleculesViral ReplicationMolecular VirologyMedicineViral Polymerase Mechanism	1995	287
Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry Darren R. Shafren, Douglas J. Dorahy, R A Ingham, Journal of Virology Molecular VirologyMedicineDecay-accelerating FactorPathogenesisViral Pathogenesis	1997	232
Interleukin-10 Gene Expression in Acute Virus-induced Asthma Terry V. Grissell, Heather Powell, Darren R. Shafren, American Journal of Respiratory and Critical Care Medicine	2005	197
Systemic Therapy of Malignant Human Melanoma Tumors by a Common Cold-Producing Enterovirus, Coxsackievirus A21 Darren R. Shafren, Gough G. Au, Tam Nguyen, Clinical Cancer Research	2004	154
A decay-accelerating factor-binding strain of coxsackievirus B3 requires the coxsackievirus-adenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells Darren R. Shafren, David T. Williams, Richard D. Barry Journal of Virology Lytic InfectionCoxsackievirus B3ImmunologyViral PathogenesisViral Structural Protein	1997	126
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer Nicola Annels, David Mansfield, Mehreen Arif, Clinical Cancer Research	2019	118
Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma Gough G. Au, Lisa F. Lincz, Arno Enno, British Journal of Haematology Oncolytic Coxsackievirus A21ImmunologyPathologyImmunotherapyTumor Biology	2007	96
The Integrins α3β1 and α6β1 Physically and Functionally Associate with CD36 in Human Melanoma Cells Rick F. Thorne, John F. Marshall, Darren R. Shafren, Journal of Biological Chemistry	2000	91
Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21 Gough G. Au, Anders Lindberg, Richard D. Barry, International Journal of Oncology Cva21 Receptor ExpressionMedicineMelanomaImmunologyCancer Growth	2005	82
Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21 Darren R. Shafren, Douglas J. Dorahy, Sandra J. Greive, Journal of Virology Molecular VirologyInfectionMouse CellsPathogenesisViral Pathogenesis	1997	71

Page 1